Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hepatitis

Free Subscription Articles published in Vaccine Retrieve available abstracts of 39 articles: HTML format

Single Articles

October 2025
1. LIU X, Han S, Wang H, Sun L, et al
   Immunogenicity and safety of co-administration of sabin-strain-based inactivated poliovirus vaccine, diphtheria-tetanus-acellular pertussis vaccine, and live attenuated hepatitis A vaccine in 18-month-old children: A multicenter randomized controlled
   Vaccine. 2025;67:127891.
   PubMed     Abstract available
   
   
   
2. COLLINS C, Ratshisusu L, Modise LM, Simani OE, et al
   Hepatitis B virus infection and vaccine coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.
   Vaccine. 2025;66:127843.
   PubMed     Abstract available
   
   
   
3. RACCAGNI AR, Morsica G, Reali P, Lolatto R, et al
   Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.
   Vaccine. 2025;66:127825.
   PubMed     Abstract available
   
   
   September 2025
4. KANG W, Wang F, Hao Z, Zhang Z, et al
   A follow-up study on the protective efficacy and anamnestic response of recombinant CHO hepatitis B vaccine 26 years after immunization.
   Vaccine. 2025;64:127743.
   PubMed     Abstract available
   
   
   August 2025
5. BARLOW M, Flanagan S, Ghosh I, Carter J, et al
   Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?
   Vaccine. 2025;63:127639.
   PubMed    
   
   
   
6. GAO L, Zhang X, Mo X, Sun Y, et al
   Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China.
   Vaccine. 2025;62:127596.
   PubMed     Abstract available
   
   
   July 2025
7. GAO S, Cai M, Su M, Zhao T, et al
   Influencing factors and trends in post-vaccination serologic testing completion rates among infants born to HBsAg-positive mothers in Guangdong Province, 2021-2023.
   Vaccine. 2025;62:127565.
   PubMed     Abstract available
   
   
   
8. LI J, Wang X, Zhang D, Xie F, et al
   Safety and immunogenicity of thiomersal-free recombinant hepatitis E vaccine: A randomized, double-blind, active-controlled study.
   Vaccine. 2025;62:127510.
   PubMed     Abstract available
   
   
   June 2025
9. SONG Y, Feng Y, Jiang F, Xu X, et al
   The HBV seroprevalence and immune responses to hepatitis B vaccination among college students from four universities in China.
   Vaccine. 2025;61:127408.
   PubMed     Abstract available
   
   
   May 2025
10. GANDHI K, Vijay Y, Page K, Dahari H, et al
    Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
    Vaccine. 2025;59:127256.
    PubMed     Abstract available
    
    
    
11. HUNG SH, Torres JL, Chen F, Giang E, et al
    Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.
    Vaccine. 2025;58:127239.
    PubMed     Abstract available
    
    
    April 2025
12. WIBOWO DP, Chalid MT, Rasyak MR, El Khobar KE, et al
    Characteristics of hepatitis B virus surface protein and occult hepatitis B infection in infants with immunoprophylaxis failure from Indonesia.
    Vaccine. 2025;56:127130.
    PubMed     Abstract available
    
    
    
13. WANG F, Zheng J, Qiu F, Yang Y, et al
    Long-term effectiveness of vaccination for prevention of hepatitis B virus mother-to-child transmission in Yunnan, China.
    Vaccine. 2025;54:127128.
    PubMed     Abstract available
    
    
    March 2025
14. OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
    Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
    Vaccine. 2025;55:127051.
    PubMed     Abstract available
    
    
    
15. VYSOTSKAYA V, Gassowski M, Kasper A, Gasich E, et al
    Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus.
    Vaccine. 2025;55:127058.
    PubMed     Abstract available
    
    
    
16. KANG M, Marks KM, Cox AL, Sherman KE, et al
    An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
    Vaccine. 2025;55:127028.
    PubMed     Abstract available
    
    
    
17. GHARPURE R, Vegvari C, Abdissa A, Alimi Y, et al
    Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.
    Vaccine. 2025;54:126860.
    PubMed     Abstract available
    
    
    January 2025
18. JIANG Y, Luo Y, Xiao X, Li X, et al
    Global, regional, and national burdens of vaccine-preventable infectious diseases with high incidence among middle-aged and older adults aged 55-89 years from 1990 to 2021: Results from the global burden of disease study 2021.
    Vaccine. 2025;49:126786.
    PubMed     Abstract available
    
    
    
19. KHETSURIANI N, Tursunova D, Kasimova R, Sharapov S, et al
    Prevalence of chronic hepatitis B virus infection among children in Uzbekistan: Impact of vaccination.
    Vaccine. 2025;48:126743.
    PubMed     Abstract available
    
    
    
20. CHIU CY, Sampathkumar P, Brumble LM, Vikram HR, et al
    Optimizing hepatitis B virus seroprotection in thoracic organ transplantation: The role of HepB-CpG (Heplisav-B) vaccination schedule.
    Vaccine. 2025;47:126705.
    PubMed     Abstract available
    
    
    
21. SEO H, Kim BJ, Oh J, Jung S, et al
    Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.
    Vaccine. 2025;47:126710.
    PubMed     Abstract available
    
    
    
22. SU Q, Qiu F, Gao Z, Zhao Y, et al
    Long-term efficacy and anamnestic response of hepatitis B vaccine derived from Chinese hamster ovary cell after 18-20 years.
    Vaccine. 2025;47:126655.
    PubMed     Abstract available
    
    
    November 2024
23. GRIGAS J, Spancerniene U, Simanavicius M, Pautienius A, et al
    Adaptive immune response to a wild boar-derived recombinant hepatitis e virus capsid protein challenge in pigs.
    Vaccine. 2024 Nov 30:126561. doi: 10.1016/j.vaccine.2024.126561.
    PubMed     Abstract available
    
    
    
24. BERTHOUD TK, Ahmed T, Nadia W, Petrov I, et al
    A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.
    Vaccine. 2024;43.
    PubMed     Abstract available
    
    
    October 2024
25. NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
    Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
    Vaccine. 2024;42:126462.
    PubMed     Abstract available
    
    
    
26. AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al
    A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
    Vaccine. 2024;42:126461.
    PubMed     Abstract available
    
    
    
27. KANG S, Chung E, Hong C, Aziz AB, et al
    Raising the case of hepatitis E: Report from the 2nd international HEV symposium.
    Vaccine. 2024;42:126398.
    PubMed     Abstract available
    
    
    September 2024
28. HOU X, Li N, Zhang H, Liu W, et al
    Hepatitis B virus infection and vaccination among people who use drugs in Xi'an, China.
    Vaccine. 2024;42:126259.
    PubMed     Abstract available
    
    
    August 2024
29. DONG R, Luo Z, Shao J, Xue H, et al
    Understanding hepatitis E vaccination intention among women of childbearing-age: A theory-based cross-sectional study.
    Vaccine. 2024;42:126258.
    PubMed     Abstract available
    
    
    
30. KANU FA, Freeland C, Nwokoro UU, Mohammed Y, et al
    Evaluation of interventions to improve timely hepatitis B birth dose vaccination among infants and maternal tetanus vaccination among pregnant women in Nigeria.
    Vaccine. 2024;42:126222.
    PubMed     Abstract available
    
    
    July 2024
31. BESBASSI H, Elias G, Meysman P, Jansens H, et al
    Modeling antigen-specific T cell dynamics following Hepatitis B Vaccination indicates differences between conventional and regulatory T cell dynamics.
    Vaccine. 2024;42:126148.
    PubMed     Abstract available
    
    
    
32. MESHRAM R, Kolte B, Gacche R
    Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept.
    Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
33. KOUTSOUMPLI G, Stasiukonyte N, Hoogeboom BN, Daemen T, et al
    An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
    Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    February 2024
34. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    January 2024
35. SANTORO PE, Paladini A, Borrelli I, Amantea C, et al
    Vaccine-preventable diseases: Immune response in a large population of healthcare students.
    Vaccine. 2024 Jan 20:S0264-410X(24)00049-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    December 2023
36. DIONNE M, Sauvageau C, Kiely M, Dahhou M, et al
    School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec.
    Vaccine. 2023 Dec 2:S0264-410X(23)01419-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    September 2023
37. SANADA T, Oda Y, Ohashi C, Isotani K, et al
    Hybrid large hepatitis B surface protein composed of two viral genotypes C and D induces strongly cross-neutralizing antibodies.
    Vaccine. 2023 Sep 20:S0264-410X(23)01096-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    
38. BIRNBAUM JA, Guttman D, Parulekar M, Omarufilo F, et al
    Eliminating hepatitis B vaccination disparities for West African immigrants.
    Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    
    
39. SUSARLA SK, Gupta M, Uttam KG, Palkar S, et al
    Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
    Vaccine. 2023 Sep 1:S0264-410X(23)01050-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.